Opus Genetics Statistics

Total Valuation

Opus Genetics has a market cap or net worth of $357.01 million. The enterprise value is $313.05 million.

Market Cap	357.01M
Enterprise Value	313.05M

Important Dates

The next estimated earnings date is Thursday, May 14, 2026, before market open.

Earnings Date	May 14, 2026
Ex-Dividend Date	n/a

Share Statistics

Opus Genetics has 71.40 million shares outstanding. The number of shares has increased by 132.91% in one year.

Current Share Class	71.40M
Shares Outstanding	71.40M
Shares Change (YoY)	+132.91%
Shares Change (QoQ)	+14.08%
Owned by Insiders (%)	14.74%
Owned by Institutions (%)	32.44%
Float	35.08M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25.15
Forward PS	20.72
PB Ratio	23.32
P/TBV Ratio	23.26
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	22.05
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.43, with a Debt / Equity ratio of 0.07.

Current Ratio	6.43
Quick Ratio	6.20
Debt / Equity	0.07
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-26.33

Financial Efficiency

Return on equity (ROE) is -242.41% and return on invested capital (ROIC) is -114.76%.

Return on Equity (ROE)	-242.41%
Return on Assets (ROA)	-55.39%
Return on Invested Capital (ROIC)	-114.76%
Return on Capital Employed (ROCE)	-90.90%
Weighted Average Cost of Capital (WACC)	7.43%
Revenue Per Employee	$507,000
Profits Per Employee	-$1.77M
Employee Count	28
Asset Turnover	0.33
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +495.10% in the last 52 weeks. The beta is 0.52, so Opus Genetics's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	+495.10%
50-Day Moving Average	4.71
200-Day Moving Average	2.56
Relative Strength Index (RSI)	48.28
Average Volume (20 Days)	706,015

Short Selling Information

The latest short interest is 1.81 million, so 2.53% of the outstanding shares have been sold short.

Short Interest	1.81M
Short Previous Month	1.85M
Short % of Shares Out	2.53%
Short % of Float	5.15%
Short Ratio (days to cover)	2.69

Income Statement

In the last 12 months, Opus Genetics had revenue of $14.20 million and -$49.59 million in losses. Loss per share was -$0.80.

Revenue	14.20M
Gross Profit	-16.62M
Operating Income	-38.60M
Pretax Income	-49.59M
Net Income	-49.59M
EBITDA	-38.55M
EBIT	-38.60M
Loss Per Share	-$0.80

Full Income Statement

Balance Sheet

The company has $45.09 million in cash and $1.13 million in debt, giving a net cash position of $43.96 million or $0.62 per share.

Cash & Cash Equivalents	45.09M
Total Debt	1.13M
Net Cash	43.96M
Net Cash Per Share	$0.62
Equity (Book Value)	15.35M
Book Value Per Share	0.22
Working Capital	42.26M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-35.25M
Capital Expenditures	n/a
Depreciation & Amortization	53,000
Net Borrowing	1.00M
Free Cash Flow	-35.25M
FCF Per Share	-$0.49

Full Cash Flow Statement

Margins

Gross Margin	-117.05%
Operating Margin	-271.90%
Pretax Margin	-349.33%
Profit Margin	n/a
EBITDA Margin	-271.53%
EBIT Margin	-271.90%
FCF Margin	n/a

Dividends & Yields

Opus Genetics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-132.91%
Shareholder Yield	-132.91%
Earnings Yield	-13.89%
FCF Yield	-9.87%

Analyst Forecast

The average price target for Opus Genetics is $9.90, which is 98.00% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.90
Price Target Difference	98.00%
Analyst Consensus	Strong Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	53.66%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Opus Genetics has an Altman Z-Score of -5.2 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-5.2
Piotroski F-Score	4